Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

The Cambridge company has aggressively reduced costs through measures including staff cuts and lower spending on research and ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Biotechnology company Moderna (NASDAQ:MRNA) in Q3 CY2025, but sales fell by 45.4% year on year to $1.02 billion. On the other ...

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.

Investing.com - Moderna (NASDAQ: MRNA) reported third quarter EPS of $-0.51, $1.54 better than the analyst estimate of $-2.05. Revenue for the quarter came in at $1.02B versus the consensus estimate ...

Qualcomm (NASDAQ:QCOM) stock dropped 1.4% as fears the chip designer will lose business from Samsung, a key customer, ...